PHIO Key Statistics, Chart & Performance
The current stock price of PHIO is 0.92 USD. In the past month the price decreased by -29.19%. In the past year, price decreased by -54.67%.
PHIO Technical Analysis
PHIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHIO. The financial health of PHIO is average, but there are quite some concerns on its profitability.
PHIO Financial Highlights
Over the last trailing twelve months PHIO reported a non-GAAP Earnings per Share(EPS) of -6.48. The EPS increased by 81.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -80.83% | ||
| Debt/Equity | 0 |
PHIO Forecast & Estimates
7 analysts have analysed PHIO and the average price target is 14.28 USD. This implies a price increase of 1452.17% is expected in the next year compared to the current price of 0.92.
PHIO Ownership
PHIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.49 | 387.092B | ||
| AMGN | AMGEN INC | 16.73 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.22 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.76 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 12.66 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.58 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHIO
Company Profile
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Company Info
PHIO PHARMACEUTICALS CORP
411 Swedeland Road, Suite 23-1080
King of Prussia PENNSYLVANIA 01752 US
CEO: Gerrit Dispersyn
Employees: 5
Phone: 15087673861
PHIO PHARMACEUTICALS CORP / PHIO FAQ
Can you describe the business of PHIO PHARMACEUTICALS CORP?
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
What is the current price of PHIO stock?
The current stock price of PHIO is 0.92 USD. The price increased by 7.38% in the last trading session.
Does PHIO stock pay dividends?
PHIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHIO stock?
PHIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for PHIO PHARMACEUTICALS CORP?
PHIO PHARMACEUTICALS CORP (PHIO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for PHIO PHARMACEUTICALS CORP?
PHIO PHARMACEUTICALS CORP (PHIO) will report earnings on 2026-03-30.
Can you provide the short interest for PHIO stock?
The outstanding short interest for PHIO PHARMACEUTICALS CORP (PHIO) is 4.61% of its float.